


Errata to the Sponsor’s Briefing Document
ReCor Medical
Circulatory System Devices Panel
August 22, 2023

Page 39, Figure 25	Corrected blood pressure values for SOLO and TRIO Cross-Over Corrected medication information below figure
--------------------	---

Figure 25: SOLO and TRIO: Change from Baseline Cross-Over Visit in Daytime Ambulatory Systolic Blood Pressure in Sham Patients who Crossed Over to Receive uRDN with Paradise System



	Baseline	2 Months	6 Months	12 Months
Patients (N)	37	37	31	32
Anti-HTN Meds (N)	1.1	1.1	1.2	1.3

	Baseline	2 Months	6 Months
Patients (N)	18	18	13
Anti-HTN Meds (N)	3.7	3.8	3.4

HTN=hypertensive; uRDN=ultrasound renal denervation

Page 110	Corrected the number of days in which deaths occurred post-procedure, which had been inadvertently switched for the sham and uRDN patients.
----------	---

The patient who received sham experienced an ST elevation resulting in myocardial infarction and death **97** days after procedure. The uRDN patient was diagnosed with metastatic pancreatic cancer and died **840** days post-procedure.